Saturday 17 October 2026 Export STVN’s income statement to Excel — free account

Stevanato Group S.p.A.

STVN Healthcare Medical Instruments & Supplies

Stevanato Group S.p.A.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 12.3% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS fell 25.0%, free cash flow fell 167.0% and total debt rose 9.27%, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for five, operating cash flow growth for three.

18.90 0.35 −1.82%

Follow STVN

Alert me

Market cap: $5.3B
P/E: 33.8×
Fwd P/E: 27.5×
Dividend yield: 0.33%
F-score: 5/9
Altman Z: 4.48
Beneish M: −2.79
Dividend safety: 63/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.56

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	4	—	3	1	—

Insider Ownership 82.08%

Capital & Financial Ratios $m

Market Cap 5,260.00

Revenue 1,425.27

Net Income 219.65

Free Cash Flow (34.67)

Net Debt 410.79

Current Ratio 1.61

Debt/Equity 0.29

P/E ratio 33.75

Fwd P/E 27.50

P/S ratio 3.62

P/B ratio 2.86

Past 5Y EPS Growth 9.21%

This Y EPS Growth 12.10%

Next Y EPS Growth 19.53%

Next Y revenue growth (5.38%)

Next 5Y EPS Growth 16.77%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 26.59%

10-year low 10-year high

P/S against its own 10 years 7.95%

10-year low 10-year high

P/B against its own 10 years 8.33%

10-year low 10-year high

EV/Sales against its own 10 years 11.52%

10-year low 10-year high

Dividends

Payout Ratio 0.11

Annual Dividend Rate 0.06

Annual Dividend Yield 0.33%

	total	individual payouts
2026	0.08	0.06
2025	0.06	0.06
2024	0.06	0.06
2023	0.06	0.06
2022	0.05	0.05
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	80	108	160	108
Receivables	390	397	400	418
Inventory	276	265	303	359
Other	187	183	204	199
	933	952	1,067	1,084

	2023	2024	2025	Q'26
Payables	301	250	298	298
ST’ Debt	155	127	140	148
Other	133	113	143	172
	622	517	606	672

Compound Annual Growth %

	10y	5y	3y
Sales	—	12.16%	9.00%
Cash Flow	—	12.73%	43.80%
Earnings	—	12.02%	1.68%
Book Value	—	36.55%	17.03%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	320	351	—	—	—
’25	270	318	354	400	1,342
’24	256	280	306	353	1,195
’23	255	278	295	345	1,175
’22	238	249	247	302	1,036
’21	232	246	253	267	998
’20	150	178	184	—	756

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	88	36	—	—	—
’25	105	59	60	99	324
’24	78	23	22	45	169
’23	40	27	36	10	114
’22	6	45	(7)	65	109
’21	7	65	20	66	158
’20	(10)	59	62	178	178

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	6	(39)	—	—	—
’25	31	(15)	(1)	(1)	15
’24	(34)	(50)	(34)	(50)	(167)
’23	(98)	(77)	(107)	(81)	(364)
’22	(56)	(34)	(42)	(15)	(147)
’21	(20)	37	(13)	22	25
’20	(10)	59	62	76	68

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.12	0.09	—	—	—
’25	0.11	0.12	0.15	0.20	0.58
’24	0.08	0.09	0.12	0.19	0.47
’23	0.12	0.14	0.15	0.18	0.60
’22	0.11	0.13	0.14	0.18	0.57
’21	0.18	0.17	0.08	0.20	0.63
’20	0.03	0.09	0.07	—	0.37

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	16.61	13.36	17.31	16.56	17.81	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	29.18	23.30	36.30	34.73	28.00
People
People	Employees	—	—	—	—	4,344	4,652	5,260	5,635	5,521	6,010
	Revenue/emp, $m	—	—	—	0.00	0.17	0.21	0.20	0.21	0.22	0.22
Income, $m
Income, $m	Revenue	—	—	—	601	756	998	1,036	1,175	1,195	1,342
	Gross margin, %	—	—	—	24.29	29.33	31.45	32.51	31.32	27.38	28.99
	EBT	—	—	—	62	110	196	198	205	173	214
	EBT margin, %	—	—	—	10.32	14.54	19.63	19.08	17.46	14.52	15.94
	Net income	—	0	—	44	110	196	198	205	173	214
	Depreciation	—	—	—	52	62	67	68	85	87	100
Per share, $
Per share, $	Revenue	—	—	—	2.27	3.14	3.95	3.92	4.43	4.41	4.92
	Earnings	—	—	—	0.17	0.37	0.63	0.57	0.60	0.47	0.58
	Cash flow	—	—	—	0.18	0.74	0.62	0.41	0.43	0.62	1.19
	Capex	—	—	—	0.00	(0.46)	(0.52)	(0.97)	(1.80)	(1.24)	(1.13)
	Free cash flow	—	—	—	0.18	0.28	0.10	(0.56)	(1.37)	(0.62)	0.05
	Book value	—	—	—	1.12	1.47	3.94	3.96	4.63	5.60	6.16
	Shares, m	—	—	—	265	241	253	265	265	271	273
Valuation, ×
Valuation, ×	P/E	—	—	—	38.33	38.33	35.45	31.23	45.03	45.40	34.69
	P/S	—	—	—	5.64	5.64	5.68	4.47	5.99	4.95	4.09
	P/B	—	—	—	10.31	10.31	5.70	4.41	5.74	3.89	3.27
	EV/Sales	—	—	—	5.95	5.95	5.46	4.42	6.29	5.25	4.37
	EV/FCF	—	—	—	16.05	16.05	215.94	(31.15)	(20.32)	(37.47)	401.67
Cash, $m
Cash, $m	Operating cash flow	—	—	—	48	178	158	109	114	169	324
	Capex	—	—	—	(83)	(110)	(133)	(256)	(478)	(336)	(309)
	Free cash flow	—	—	—	48	68	25	(147)	(364)	(167)	15
Balance, $m
Balance, $m	Working capital	—	—	—	210	202	624	404	311	436	461
	Total debt	—	—	—	433	429	294	231	432	470	533
	Net debt	—	—	—	291	249	(225)	(45)	352	363	373
	Shareholders’ equity	—	—	—	298	354	996	1,049	1,226	1,520	1,682
Returns, %
Returns, %	ROA	—	—	—	8.89	8.56	11.41	8.78	7.90	5.35	5.86
	ROIC	—	—	—	0.00	12.20	15.55	12.62	8.61	5.79	6.84
	ROE	—	—	—	12.98	27.50	23.54	14.72	13.86	9.28	9.88

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ATR AptarGroup, Inc.	$7.9B	22.2×	21.0×	+6.26% (above 0%: growing)	−18.34% (below 0%: shrinking)	−23.07% (below 0%: shrinking)	35.61%	12.34%	Compare
BLCO Bausch + Lomb Corporation	$6.0B	— (loss-making)	— (loss-making)	+9.08% (above 0%: growing)	n/m	+251.85% (above 0%: growing)	62.20%	5.95%	Compare
TFX Teleflex Incorporated	$5.4B	— (loss-making)	45.3×	+28.88% (above 0%: growing)	−17.33% (below 0%: shrinking)	+220.14% (above 0%: growing)	58.16%	12.77%	Compare
MMSI Merit Medical Systems, Inc.	$5.4B	36.4×	23.4×	+9.51% (above 0%: growing)	+18.18% (above 0%: growing)	−25.66% (below 0%: shrinking)	51.37%	14.42%	Compare
STVN Stevanato Group S.p.A.	$5.3B	33.8×	27.5×	+10.46% (above 0%: growing)	−25.00% (below 0%: shrinking)	−167.02% (below 0%: shrinking)	28.75%	12.93%
ICUI ICU Medical, Inc.	$4.2B	136×	49.5×	+0.51% (above 0%: growing)	−46.85% (below 0%: shrinking)	+655.98% (above 0%: growing)	42.61%	7.09%	Compare
NVST Envista Holdings Corporation	$3.8B	38.8×	24.4×	+7.10% (above 0%: growing)	+106.25% (above 0%: growing)	+37.57% (above 0%: growing)	55.72%	10.99%	Compare
PLSE Pulse Biosciences, Inc	$3.3B	— (loss-making)	— (loss-making)	+4,922.22% (above 0%: growing)	n/m	−45.39% (below 0%: shrinking)	37.10%	(5,823.04%)	Compare
WRBY Warby Parker Inc.	$3.0B	334×	122×	+9.81% (above 0%: growing)	n/m	−71.75% (below 0%: shrinking)	57.94%	1.34%	Compare
Median of peers	$4.8B	38.8×	34.8×	+9.30%	−17.33%	+7.25%	53.55%	9.04%

All 55 Medical Instruments & Supplies stocks →

Stevanato Group S.p.A. (STVN) key facts

Strength: Stevanato Group S.p.A.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 12.3% from fiscal 2024.
Strength: Net income was $214.0 million, or $0.58 per share (basic), a net margin of 11.8%.
Stevanato Group S.p.A. (STVN) is a Medical Instruments & Supplies company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, STVN traded at $18.90, a market capitalization of $5.3 billion.
At that price the stock trades at 33.8× trailing-twelve-month earnings and 3.6× sales; its P/E is higher than 27% of its own readings over the past ten years.
Stevanato Group S.p.A. pays an annual dividend of $0.06 per share, a yield of 0.33%, with a payout ratio of 11.2%.
Return on equity was 9.88% and debt-to-equity 0.29.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 4.48 (safe zone) for fiscal 2025.